Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression

<p>Figure S.6</p>

Salvato in:

Dettagli Bibliografici
Autore principale:	Xufeng Lu (14960724) (author)
Altri autori:	Dazhuan E. Xin (14960727) (author), Juanjuan K. Du (14960730) (author), Quanli C. Zou (14960733) (author), Qian Wu (14960736) (author), Yanan S. Zhang (14960739) (author), Wenhai Deng (14960742) (author), Jicheng Yue (14960745) (author), Xing S. Fan (14960748) (author), Yuanyuan Zeng (9330065) (author), Xiaju Cheng (14960751) (author), Xue Li (14960754) (author), Zhaoyuan Hou (14960757) (author), Man Mohan (14960760) (author), Ting C. Zhao (14960763) (author), Xiaomei Lu (14960766) (author), Zhijie Chang (14960769) (author), Liyan Xu (14960772) (author), Yu Sun (14960775) (author), Xiongbing Zu (14960778) (author), Yu Zhang (14960781) (author), Y. Eugene Chinn (14960784) (author)
Pubblicazione:	2025
Soggetti:	Cancer Cancer Biology Immuno-oncology Gynecological Cancers Uterine cancer Immunotherapy Combination immunotherapy Oncogenes & Tumor Suppressors Tumor suppressor genes
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
di: Renumathy Dhanasekaran (14962092)
Pubblicazione: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
di: Daniel S. Green (15047598)
Pubblicazione: (2025)

Supplementary Figure 1 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
di: Bo Yan (15062907)
Pubblicazione: (2025)

Supplementary Figure 2 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
di: Bo Yan (15062907)
Pubblicazione: (2025)

Supplementary Figure 3 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
di: Bo Yan (15062907)
Pubblicazione: (2025)

Supplementary Figure 4 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
di: Bo Yan (15062907)
Pubblicazione: (2025)

Supplementary Table 1 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
di: Bo Yan (15062907)
Pubblicazione: (2025)

Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
di: John Powderly (15026168)
Pubblicazione: (2025)

Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
di: John Powderly (15026168)
Pubblicazione: (2025)

Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
di: John Powderly (15026168)
Pubblicazione: (2025)

Figure S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
di: John Powderly (15026168)
Pubblicazione: (2025)

Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
di: John Powderly (15026168)
Pubblicazione: (2025)

Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
di: John Powderly (15026168)
Pubblicazione: (2025)

Table 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
di: John Powderly (15026168)
Pubblicazione: (2025)

Table 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
di: John Powderly (15026168)
Pubblicazione: (2025)

Table S1 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
di: Morgane Lecointre (21652429)
Pubblicazione: (2025)

Table S2 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
di: Morgane Lecointre (21652429)
Pubblicazione: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Supplementary Data1 from Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and Plasma
di: Namsoo Kim (21718000)
Pubblicazione: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
di: Diwakar Davar (15023480)
Pubblicazione: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
di: Diwakar Davar (15023480)
Pubblicazione: (2025)